The V2 receptor antagonist tolvaptan counteracts proliferation and invasivity in human cancer cells

被引：0
|
作者：
G. Marroncini
C. Anceschi
L. Naldi
B. Fibbi
F. Baldanzi
M. Maggi
A. Peri
机构：
[1] AOU Careggi,Pituitary Diseases and Sodium Alterations Unit
[2] University of Florence,Endocrinology, Department of Experimental and Clinical Biomedical Sciences “Mario Serio”
[3] AOU Careggi,undefined
来源：
Journal of Endocrinological Investigation | 2022年 / 45卷
关键词：
Tolvaptan; AVP receptors; Hyponatremia; Cancer; SIAD;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1693 / 1708
页数：15
相关论文
共 50 条
  • [21] Molecular modelling of the vasopressin V2 receptor/antagonist interactions
    Czaplewski, C
    Kazmierkiewicz, R
    Ciarkowski, J
    ACTA BIOCHIMICA POLONICA, 1998, 45 (01) : 19 - 26
  • [22] The Vasopressin Receptor Antagonist Tolvaptan Counteracts Tumor Growth in a Murine Xenograft Model of Small Cell Lung Cancer
    Naldi, Laura
    Fibbi, Benedetta
    Polvani, Simone
    Cirillo, Chiara
    Pasella, Francesca
    Bartolini, Francesca
    Romano, Francesca
    Fanelli, Alessandra
    Peri, Alessandro
    Marroncini, Giada
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (15)
  • [23] Conivaptan:: A dual receptor vasopressin V1a/V2 antagonist
    Ali, Farhan
    Raufi, M. Adnan
    Washington, Barbara
    Ghali, Jalal K.
    CARDIOVASCULAR DRUG REVIEWS, 2007, 25 (03): : 261 - 279
  • [24] Vasopressin V2 receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia
    Gheorghiade, M
    Gottlieb, SS
    Udelson, JE
    Konstam, MA
    Czerwiec, F
    Ouyang, J
    Orlandi, C
    AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (07): : 1064 - 1067
  • [25] Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia
    Schrier, Robert W.
    Gross, Peter
    Gheorghiade, Mihai
    Berl, Tomas
    Verbalis, Joseph G.
    Czerwiec, Frank S.
    Orlandi, Cesare
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (20): : 2099 - 2112
  • [26] Effects of the vasopressin V2 receptor antagonist, tolvaptan, on the long-term progression of left ventricular dilatation in patients with heart failure
    Udelson, JE
    Mcgrew, F
    Flores, E
    Ibrahim, H
    Koshkarian, G
    Katz, S
    O'Brien, T
    Zimmer, C
    Konstam, MA
    JOURNAL OF CARDIAC FAILURE, 2005, 11 (09) : 720 - 720
  • [27] Effects of the vasopressin V2 receptor antagonist, tolvaptan, on the long-term progression of left ventricular dilatation in patients with heart failure
    Udelson, JE
    McGrew, F
    Flores, E
    Ibrahim, H
    Koshkarian, G
    Katz, S
    O'Brien, T
    Johnson, RH
    Zimmer, C
    Orlandi, C
    Konstam, MA
    CIRCULATION, 2005, 112 (17) : U564 - U564
  • [28] THE EFFECTS OF A VASOPRESSIN V2 RECEPTOR ANTAGONIST IN THE MANAGEMENT OF PATIENTS WITH CIRRHOSIS AND HYPONATREMIA. SAFETY AND EFFICACY OF ORAL TOLVAPTAN IN THE SALT TRIALS
    Cardenas, Andres
    Gines, Pere
    Marotta, Paul
    Czer-wiec, Frank S.
    Ouyang, John
    Sexton, Anne
    Guevara, Monica
    Afdhal, Nezam H.
    HEPATOLOGY, 2009, 50 (04) : 467A - 468A
  • [29] Tolvaptan, an orally active non-peptide arginine vasopressin V2 receptor antagonist, reduces ascites in rats with chronic liver injury
    Miyazaki, Toshiki
    Fujiki, Hiroyuki
    Yamamura, Yoshitaka
    HEPATOLOGY RESEARCH, 2013, 43 (11) : 1224 - 1230
  • [30] Tolvaptan (OPC-41061), a V2 vasopressin receptor antagonist, protects against the decline in renal function observed with loop diuretic therapy
    Burnett, JC
    Costello-Boerrigter, LC
    Smith, WB
    Ouyang, J
    Zimmer, CA
    Orlandi, C
    CIRCULATION, 2003, 108 (17) : 398 - 398
12345